Lonza Capabilities Update October 2026: Fill/Finish

As biologics pipelines diversify and regulatory scrutiny intensifies, drug product manufacturing strategies must combine proven technical capabilities with the flexibility to transfer, launch and scale reliably across modalities, formulations and facilities. In this Outsourced Pharma Capacity Update, Bastian Klöfer, Director, Commercial Development, Drug Product Services at Lonza, presents how Lonza’s integrated, end-to-end biologics network combines drug substance expertise, drug product development and manufacturing, analytical capabilities, technology transfer and regulatory support across liquid and lyophilized vials, prefilled syringes, cartridges and highly potent products.